Submit Content
Get the latest delivered to your inbox
Privacy Policy

Moderna Launches New Charitable Foundation

Initial grants of approximately $5 million awarded to local and global nonprofits that support groups and causes disproportionately affected by COVID-19

Published 04-04-22

Submitted by Moderna

CAMBRIDGE, Mass., April 4, 2022 /CSRwire/ - Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the launch of the Moderna Charitable Foundation to promote public health, access to quality healthcare and educational opportunities, particularly in underserved populations.

“We founded Moderna based upon the idea that we can make a transformative positive impact through our medicines, and the work of the Moderna Charitable Foundation will accelerate our efforts to improve health globally, particularly for those with inadequate access to health and medicine,” said Noubar Afeyan, Co-founder and Chairman of Moderna. “We established the Moderna Foundation to support organizations that share our commitment to bettering the lives of patients, and to addressing inequalities that have been highlighted by the pandemic. I look forward to all we accomplish together.”

“The Moderna Foundation is an extension of the positive societal impact we have made following the development of our COVID-19 vaccine and reflects our continued commitment to communities impacted by COVID-19,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We are excited to extend our social impact and support the causes our employees care most about as we work relentlessly to improve human health with our mRNA technology.”

The Moderna Foundation was established by the Moderna Board of Directors, which approved an initial up-front endowment of $50 million. The Foundation and its grant program will focus on charitable programs with a particular emphasis on supporting local and global communities impacted by the pandemic, advancing scientific education and innovation, promoting public health and access to healthcare, and advocating for inclusion and diversity.

Today, the Moderna Foundation announced approximately $5 million in initial grants to five local and global nonprofit organizations working to address these areas of need, including:

  • Boston Medical Center’s Good Grief Program, to help meet growing demand for trauma-informed, culturally responsive therapeutic services for children who have experienced loss, such as the death of a loved one due to COVID-19
  • Heading Home, to provide permanent, supportive housing for extremely low-income individuals in Cambridge, Massachusetts
  • International Rescue Committee, to support infection prevention and control programs for improved and resilient health systems in West and Central Africa, particularly in countries that have been impacted by conflict
  • Life Science Cares, to support nonprofit partnerships and programs fighting poverty and its effects in the Greater Boston Area
  • Year Up, to support a workforce development program that closes the opportunity divide between young adults and companies across the U.S.

“We are incredibly proud to have been able to play a role in fighting the global pandemic with our COVID-19 vaccine, but we know that there is so much more that needs to be done to address the pandemic’s longer term societal impact,” said Shannon Thyme Klinger, President of the Moderna Charitable Foundation. “The Foundation is another example of Moderna’s dedication to Corporate Social Responsibility. With programs designed to help people disproportionately affected by COVID-19 and the unprecedented disruption that has resulted from the pandemic, we look forward to supporting the Foundation’s partners to make a lasting impact in communities across the globe.”

Organizations that are aligned with the Foundation’s mission and seeking grant support can visit www.modernatx.com/foundation to learn more.

The Foundation also offers Moderna employees the opportunity to give back to their communities and directly support causes that they are passionate about through the Foundation’s matching volunteer and donation programs.

About Moderna

In 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

About The Moderna Charitable Foundation

The Moderna Charitable Foundation is a nonprofit organization that seeks to promote public health, access to quality healthcare, advancing scientific education and innovation, and advocating for diversity and inclusion. The Foundation focuses on supporting underserved populations, with particular focus on serving local and global communities impacted by COVID-19. Find out more about the Moderna Charitable Foundation at www.modernatx.com/foundation.

5 corporation logos

Media
Kate O’Malley
Senior Director, Communications
Katherine.Omalley@modernatx.com

Moderna logo

Moderna

Moderna

About Moderna
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

More from Moderna

Join today and get the latest delivered to your inbox